Biotech Stocks Shift: XBI Gains Amid Tech Rotation and Wells Fargo’s Argenx Pick

US markets, as technology leaders retreat, are seeing investors rotate into biotech, lifting the XBI ETF while major indices shed AI‑heavy stocks.

Tech Wane Sparks Sector Rotation

■Tech giants’ valuations have slipped %10 amid profit‑taking (e.g., NVIDIA, Microsoft).

■Capital is flowing from AI dominance into defensive health‑care names.

■The XBI biotech ETF posted a %7 gain last week, whereas the S&P 500 and Nasdaq slipped %3.

Wells Fargo’s Argenx Recommendation and Catalyst

■Wells Fargo flagged Argenx as a top Q3 tactical pick.

■The company awaits FDA clearance for a new monoclonal antibody, a potential Q3 catalyst.

■Argenx’s market cap stands at $9.8 billion, with a target price of $180.

Biotech’s Market Impact and Strategic Opportunities

■Intra‑sector rotation can improve risk diversification for tech‑heavy portfolios.

■Biotech’s low‑correlation returns add stability in volatile environments.

■Analysts expect M&A activity in the sector to accelerate through Q4.

Gökberk Uçar: The recent biotech rally is more than a short‑term reflex; it reflects enduring support for long‑term health‑care technology investments. By shifting exposure from overvalued AI stocks to biotech, investors can hedge against valuation risk and build a more resilient portfolio.